Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30826903 | 0.92 | SMARCA2 (0.41) | GPR119SMARCA2SMARCA4PBRM1TLR9 | |
| SCHEMBL28515675 | 0.92 | SMARCA2 (0.41) | GPR119SMARCA2SMARCA4PBRM1TLR9 | |
| SCHEMBL28515676 | 0.92 | SMARCA2 (0.41) | GPR119SMARCA2SMARCA4PBRM1TLR9 | |
| SCHEMBL28997459 | 0.90 | SMARCA2 (0.41) | GPR119SMARCA2SMARCA4PBRM1TLR9 | |
| SCHEMBL30335662 | 0.90 | SMARCA2 (0.41) | GPR119SMARCA2SMARCA4PBRM1TLR9 | |
| SCHEMBL28997461 | 0.90 | SMARCA2 (0.41) | GPR119SMARCA2SMARCA4PBRM1TLR9 | |
| SCHEMBL28503228 | 0.84 | GPR119 (0.41) | GPR119SMARCA2SMARCA4PBRM1MET | |
| SCHEMBL28503226 | 0.84 | GPR119 (0.41) | GPR119SMARCA2SMARCA4PBRM1MET | |
| SCHEMBL28846833 | 0.83 | GPR119 (0.42) | GPR119SMARCA2SMARCA4PBRM1MET | |
| SCHEMBL29026649 | 0.83 | GPR119 (0.42) | GPR119SMARCA2SMARCA4PBRM1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409558-A1 | IRREVERSIBLE INHIBITORS OF KRAS | BIOMEA FUSION, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2023039240-A9 | IRREVERSIBLE INHIBITORS OF KRas | BIOMEA FUSION, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023039240-A9 | IRREVERSIBLE INHIBITORS OF KRas | BIOMEA FUSION, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023039240-A1 | IRREVERSIBLE INHIBITORS OF KRas | BIOMEA FUSION, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409558-A1 | IRREVERSIBLE INHIBITORS OF KRAS | KRAS, NRAS, TP53 | GPR119 1372/4885SMARCA2 1899/4885SMARCA4 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.